This website uses cookies to ensure you get the best experience on our website.
Accept Cookies
Learn More
Green Journals
Home
Hijacked
Contact Us
More
Simulation
Green Recruitments
About Us
Blog
Login
Register
English
English
Français
العربية
Journal Report
GaBI Journal
Download PDF
Print
Journal Information
Journal Title
GaBI Journal
Publisher
Pro Pharma Communications International
ISSN
2033-6403
E-ISSN
2033-6772
Database
SCOPUS
Domain
Health Sciences, Life Sciences, Physical Sciences, Social Sciences
Classification History
Year
A+
A
B
C
2026
✓
2025
✓
2024
2023
✓
2021/2022
✓
2020
✓
2019
✓
2018
A journal may have more than one classification in the same year. All recorded classifications are displayed.
Recent Articles
Effective and safe handling of pre-filled syringe (PFS) for administration of biosimilar candidate AVT06 (aflibercept) in patients with chorioretinal vascular diseases
Silvia Cirillo, Riken Soni, Masna Rai et al.
2025-12-15
Vol. 14
Issue 3
Pages 85-92
DOI:
10.5639/gabij.2025.1403.016
Biosimilars in oncology: beyond regulation—building confidence through evidence and dialogue
César Humberto Oyarzo Mansilla
2025-12-15
Vol. 14
Issue 3
Pages 73-73
DOI:
10.5639/gabij.2025.1403.013
Australian biosimilar policies not delivering on intended outcomes: where to from here?
Chad Rieger, Clint Holland
2025-12-15
Vol. 14
Issue 3
Pages 93-102
DOI:
10.5639/gabij.2025.1403.017
Barriers to expanding biosimilars in oncological indications in Chile: A value-chain approach to understand visions and propose recommendations for improving value proposition
Daniela Maria Paredes-Fernández, Rony Christian Lenz-Alcayaga
2025-12-15
Vol. 14
Issue 3
Pages 75-84
DOI:
10.5639/gabij.2025.1403.015
Rising costs of biologicals: effective cost-containment does not please all stakeholders
Pekka Kurki
2025-12-15
Vol. 14
Issue 3
Pages 74-74
DOI:
10.5639/gabij.2025.1403.014
Turkey’s biotech manufacturing ambitions: Yerlika Biopharma’s strategic role
2025-8-15
Vol. 14
Issue 2
Pages 63-65
DOI:
10.5639/gabij.2025.1402.010
Biosimilar trial failed? Investors get their money back: a new insurance model redefines clinical trial financing
Tomas J Philipson, Dhruva Gupta, Jacob Shia et al.
2025-8-15
Vol. 14
Issue 2
Pages 68-69
DOI:
10.5639/gabij.2025.1402.011
Follow-on biologicals/biosimilars approved in Brazil: September 2025 update
Sílvia Helena Cestari de Oliveira, German Enrique Wassermann
2025-8-15
Vol. 14
Issue 2
Pages 47-52
DOI:
10.5639/gabij.2025.1402.008
Current trends in biosimilar uptake and special focus on automatic substitution – a symposium report
Alan Lyles, E Heinonen, HM Tolonen et al.
2025-8-15
Vol. 14
Issue 2
Pages 53-62
DOI:
10.5639/gabij.2025.1402.009
A spectrum of generics and biosimilars: research, reports, and interviews
Robin Thorpe
2025-8-15
Vol. 14
Issue 2
Pages 39-39
DOI:
10.5639/gabij.2025.1402.006
Articles retrieved from Crossref.
Green Journals | https://www.green-journals.com | info@green-journals.com
Printed: November 20, 2026 17:06